Bone marrow examination is integral to the diagnosis of hematologic disorders and is also important to determine the stage and treatment of hematologic and other malignancies. The most common indications for bone marrow examinations in general patient populations including children and adults are for the diagnosis and management of acute leukemia and staging for lymphoma. 1,2 Little published literature is available regarding the indication and diagnostic usefulness of bone marrow biopsies specifically in the extreme elderly population defined as patients 85 years or older. It seems likely that the indications and diagnoses made, as well as the impact of these diagnoses on therapy, would be different for this subpopulation. This information is of interest as the population of the United States ages and the number of elderly patients undergoing bone marrow biopsy may increase. It is of particular interest to our institution, a public tertiary care center in a state with one of the highest percentages of elderly people.
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Materials and Methods
Bone marrow records from the hematopathology laboratory in the Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, from January 2002 to December 2006, were searched, and cases from all patients at least 85 years old at the time of biopsy were retrospectively reviewed. Patient age, sex, indication and clinical history provided by the patient's physician, and diagnosis were recorded for each of the cases. The indications were classified into the following categories: cytopenias (1 or more); followup of a previously diagnosed (before the age of 85 years) myelodysplastic syndrome (MDS) or MDS-transformed acute myelogenous leukemia (AML); suspicion of plasma cell myeloma (PCM); follow-up of previously diagnosed PCM, thrombocytosis, or leukocytosis; follow-up or staging of a previously diagnosed lymphoma or chronic leukemia; or other, for indications that could not be placed in one of the previously named categories. Excluding the cases with previously known diagnoses, the number of biopsies that provided specific diagnoses was determined in total and by biopsy indication. Results of cytogenetic analysis were also recorded. Chart review was also performed for all patients who were seen at University of Iowa Hospitals and Clinics to determine how the biopsy affected clinical management and whether the patients received disease-modulating therapy. For patients who received therapy, whether they received abbreviated or modified treatment regimens was also recorded.
Results
During the 5-year period, 13,251 bone marrow biopsy examinations were performed, and of these, 119 (0.9%) were in patients at least 85 years old. There were similar numbers of men (65) and women (54), and the age range of the patients was 85 to 99 years. In all of these cases, the biopsy specimens were considered adequate for making a diagnosis.
Reasons for biopsies included unexplained decrease in 1 The latter included cases with multiple or complex indications that could not be classified into one of the specific categories. Of the 43 biopsies performed for cytopenias, 23 were for a decrease in 2 cell lineages or pancytopenia, 16 were for anemia, 3 for thrombocytopenia, and 1 for leukopenia (Table 1) . In these patients, the hemoglobin levels ranged from 6.7 to 11.6 g/dL (67-116 g/L), platelet counts from 29 to 120 × 10 3 /µL (29-120 × 10 9 /L), and WBC counts from 1,500 to 4,500/µL (1.5-4.5 × 10 9 /L).
Excluding 40 biopsies that were performed for follow-up or staging of previously known diseases, 34 (43%) of 79 cases yielded specific diagnoses. Myelodysplasia was diagnosed in 11 patients, myeloproliferative neoplasms (MPNs) in 10 patients, PCM in 5 patients, lymphoproliferative disorders in 5 patients, and acute leukemia in 3 patients zTable 2z. Of 43 biopsies for cytopenia, 13 (30%) yielded specific diagnoses, and plasma cell dyscrasias were diagnosed in 5 of 13 patients who underwent biopsy for suspicion of PCM. Diagnoses made in patients who underwent biopsy for cytopenias were MDS (11 patients) or AML (2 patients). Of the 17 biopsies for leukocytosis or thrombocytosis, 14 yielded specific diagnoses, including 8 of 10 for thrombocytosis and 6 of 7 for leukocytosis. Patients who underwent biopsy for thrombocytosis were most often given a diagnosis of essential thrombocythemia or chronic idiopathic myelofibrosis, and patients who underwent biopsy for leukocytosis were given diagnoses of a variety of acute and chronic leukemias, including T-prolymphocytic leukemia, chronic myelomonocytic leukemia, chronic lymphocytic leukemia, and acute myelogenous leukemia zTable 3z. Cytogenetic information was reported in 23 cases. In 13 cases with cytopenias, the results were normal in 11; 5q-was present in 2, and 1 of these cases also had a trisomy 8. Cytogenetic abnormalities were found in 3 cases with a previous diagnosis of MDS. In 4 cases of essential thrombocythemia, the results of cytogenetic studies were normal; 1 patient with chronic myelomonocytic leukemia had 1q+, and the patient with chronic myelogenous leukemia had t(9;22).
Follow-up information was available for 45 patients. In total, 20 of 45 patients received disease-modulating therapy, and 17 of the 20 received abbreviated or modified therapies owing to poor performance status or drug intolerance. The 3 patients who did not receive modified therapies were being treated for PCM with melphalan and prednisone. Nine patients were treated for lymphoma, 5 for PCM, 3 for AML, and 3 for MPN or MDS zTable 4z.
Discussion
Few data have been published about the use of bone marrow biopsies in extremely elderly patients, although it is likely that as our population ages, more biopsies will be performed in elderly patients. It also seems that the indications and diagnostic usefulness of biopsies in elderly patients differ from those of bone marrow biopsies in patient populations composed of children or young to middle-aged adults. Studies of general patient populations have shown that the most common indications for bone marrow biopsy include diagnosis and management of acute leukemia and staging for lymphoma. 1, 2 In this study, cytopenias were the most common indication, accounting for 36.1% of biopsies. Other common indications in this study, including suspicion of PCM, thrombocytosis, leukocytosis, and follow-up of a known MDS, were rarer indications in general patient populations. 1,2 Follow-up or staging of lymphoma was still a common indication in elderly patients but accounted for fewer than 11% of biopsies. Few biopsies were performed for suspicion of acute leukemia without a history of MDS.
It is known that there is an increase in the incidence of leukemia, lymphoma, MDS, and MPN with age and that MDS and MPN are rare in children and young adults. 3 Excluding the biopsies for follow-up or staging of previously known diseases, MDS and MPN were the most common new diagnoses in patients at least 85 years old, each accounting for almost one third of all new diagnoses. This finding differs significantly from the previously referenced studies of biopsies in general hospital populations, in which the most common diagnoses were acute leukemias and lymphomas, although it is unclear if these studies included repeated biopsies during therapy and staging of leukemia and lymphoma in their numbers. 1,2 Of note, in this study, chronic lymphocytic leukemia (CLL) was an uncommon diagnosis made by bone marrow biopsy. In our institution, the diagnosis is typically based on evaluation of a peripheral blood smear and flow cytometry of the peripheral blood sample. Only 1 case of CLL was newly diagnosed by bone marrow biopsy, and 2 other biopsies were for follow-up and staging of CLL.
In this study, the indications that resulted in the highest yield of specific diagnoses in biopsies were thrombocytosis and leukocytosis. Cytopenias, while the most common indication, resulted in the lowest biopsy diagnostic yield, and their clinical significance most likely came from excluding common clonal causes of cytopenia, including MDS. In addition, patients who underwent biopsy owing to unexplained cytopenias often did not receive disease-modulating therapy as a consequence of the biopsy, although follow-up information was available for only a small number of patients. In this category, 2 of 6 patients were treated, 1 for a higher grade MDS (refractory anemia with excess blasts) and 1 for AML. The patients who had diagnostic biopsies and did not receive treatment had low-grade MDS or a performance status precluding aggressive therapy. For patients who were treated for leukemia and lymphoma, all received abbreviated or modified therapies and all had poor outcomes defined as treatment failure and death.
The most common indication for biopsy in this study was 1 or more decreases in CBC count parameters, especially anemia, and this indication was the least likely to yield a specific diagnosis on biopsy. The severity of the anemia that prompted a bone marrow aspirate was variable; some patients were severely anemic, whereas others were only mildly so.
Although it is known that the hematopoietic system is modestly affected by age as indicated by the continuous decrease in bone marrow hematopoietic elements, normal aging does not cause significant decreases in blood cell count parameters. [3] [4] [5] [6] [7] [8] [9] However, anemia is very common in elderly patients and is considered an important cause of morbidity. Even mild anemia has been shown to have a significant impact on the quality of life in elderly patients. Most cases of anemia in elderly patients are due to nutritional deficiency, chronic inflammation, chronic kidney disease, or MDS, although in many patients, the etiology remains unexplained. [5] [6] [7] In an elderly patient with anemia, the bone marrow biopsy would ideally be used to exclude or confirm the diagnosis of myelodysplasia or other serious hematolymphoid disease and to help guide therapy. This goal can be a complicated task because at least one study has shown that dysplastic changes are observed more frequently in bone marrow biopsy specimens of patients 60 years or older. 10 In addition, the US Food and Drug Administration-approved therapies for MDS, the most common diagnosis made in patients with cytopenias in this study and one of the relatively more common causes of anemia in elderly patients, cause significant neutropenia and thrombocytopenia and have not been shown to improve overall survival. 11 It seems that bone marrow examination would not likely alter clinical management or outcome for most elderly patients with cytopenias, specifically anemia.
Although bone marrow biopsies are safe, with reported complication rates of 0.05%, 3, 4, 12 it might be suggested that age-related frailty may result in increased morbidity from bone marrow biopsies, although data on age-related incidence of bone marrow complications are sparse. A large study in 2003 that looked at bone marrow biopsy morbidity and mortality did not report the age of patients who experienced complications but concluded that MPNs, diseases increasingly common in elderly patients, were one of the most common potential risk factors. 12 The finding that most patients who underwent biopsy for cytopenias in this study did not receive specific diagnoses or altered therapy after the biopsy may suggest that higher thresholds for bone marrow biopsy may be indicated in a subset of elderly patients. Patients with poor performance status or mild decreases in CBC count parameters or in whom there is a low suspicion for high-grade clonal neoplasms may benefit from simple supportive therapy and follow-up to avoid the cost and potential morbidity from bone marrow biopsy.
